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BUSPIRONE PHARMACOKINETICS IN AUTISTIC CHIL-
DREN. D. Edwards, PharmD, D. C. Chugani, PhD, H. T. Chugani,
MD, J. Chehab, M. Malian, J. V. Aranda, MD, PhD, Wayne State
University, Children’s Hospital of Michigan, NICHD-PPRU Net-
work, Detroit, MI.
BACKGROUND/AIMS: PET studies of alpha[C-11]methyl-
tryptophan show that brain serotonin synthesis is elevated between 2
and 6 years of age. This process is disrupted in autistic children
suggesting that the 5HT1A agonist buspirone might be useful in
treating autism. Since there are no published PK data in young
children, we studied the disposition of buspirone in autistic children
aged 2 to 6 years.
METHODS: Subjects (5 males, 3 females) received a single oral
dose of buspirone solution [2.5 mg for 2–3 year olds (n5); 5.0 mg
for 4–6 year olds (n3)]. Blood was collected for 8 hours and
plasma assayed for buspirone and the major metabolite
1-pyrimidylpiperazine (1-PP) using LC-MS.
RESULTS: The mean peak concentration of buspirone was
1101  827 pg/mL with a median tmax of 0.5 hours. Oral clearance
(Cl/F) averaged 91.5 L/hr/kg with an elimination half-life of
1.50.15 hours. Peak concentrations of 1-PP were 5.7-fold higher
than for buspirone with a metabolite half-life of 4.1 hours. There was
no evidence of non-linearity in buspirone or 1-PP disposition over the
dose range studied.
CONCLUSIONS: The data indicate extensive metabolism in
young children. Plasma concentrations and PK parameters for buspi-
rone and 1-PP were similar to values observed in older children
receiving 7.5–15 mg doses. Doses of 2.5–5 mg should be appropriate
for younger children.
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EFFECT OF MDR1 GENOTYPE (G2677T) ON THE DISPOSI-
TION OF CIPROFLOXACIN IN ADULTS. J. C. Gorski, PhD, J. L.
Renbarger, MD, R. Vuppalanchi, MD, M. Miller, PhD, R. E. Galin-
sky, PharmD, S. D. Hall, PhD, Indiana University School of Med-
icine, US FDA Office of Women’s Health, Purdue University School
of Pharmacy, Indianapolis, IN.
BACKGROUND: Some fluoroquinolone antibiotics are sub-
strates of MDR1. The aim of this study was to assess the effect of
MDR1 genotype on the disposition of ciprofloxacin (C).
METHODS: 24 volunteers weighing 6610 kg (meanSD) with
a mean age of 3319 yrs completed the study after giving written
informed consent. A single oral dose of C (500mg) was given and
serial blood samples obtained. Serum C concentrations were deter-
mined using HPLC with UV detection. MDR1 exon 21 genotype
(G2677T/A) was determined using real time RT-PCR.
RESULTS: MDR1 homozygous variant (G2677T) subjects (n 
7) had a significantly (p  0.05) reduced oral clearance of C com-
pared to individuals with 1 or 2 wild-type alleles (36  6 vs. 49.5 
14 L/h). AUC and CMAX of C were significantly greater in homozy-
gous variant individuals (14.02.1 mg  hr/L, 3.00.8 mg/L) com-
pared to wild-type allele carriers (10.9  3.3 mg  hr/L, 2.1 0.8
mg/L, P  0.05).
CONCLUSION: MDR1 exon 21 homozyogous variant (G2677T)
subjects have a reduced C clearance and may have an enhanced
efficacy and increased incidence of adverse events.
Supported by the NIH (M01-RR00750) and FDA Office of Wom-
en’s Health (HHS 233-02-0066).
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CHARACTERIZATION OF P-GLYCOPROTEIN INHIBITION
AT THE BLOOD BRAIN BARRIER BY KETOCONAZOLE AND
QUINIDINE USING THE CENTRAL PHARMACODYNAMICS
OF LOPERAMIDE AS AN INDICATOR OF BRAIN DISTRIBU-
TION. T. Fullerton, PharmD, M. Bednar, MD, PhD, P. Raava, MS,
J. Legg, BS, D. Hoelscher, MD, D. Eckols, BS, M. Gibbs, PhD,
Medical and Development Sciences, Pfizer Inc, PPD International,
Groton, CT.
BACKGROUND: Loperamide (L) is a  opioid agonist that does
not cause central opiate effects, presumably due to P-glycoprotein
(Pgp) mediated efflux from the brain. L is a substrate for both CYP3A
and Pgp. Ketoconazole (K) is a potent inhibitor of CYP3A. Quinidine
(Q) and K inhibit Pgp. This study evaluated the ability of L to induce
opioid effects in the presence of K or Q.
METHODS: In a 2 part trial, 8 & 10 subjects were studied after
the steady state K (400 mg QD) or single-dose Q (100, 400, 800 mg)
arms. L doses up to 16 mg were studied. Subjects received oral
morphine (M) 30 mg as a positive control. Pupil diameter was
measured via pupilometry. PK and PD parameters were determined
using WinNonLin.
RESULTS: PK and PD parameters (adjusted geometric means)
for L 16 mg are noted in following table:
Rx K P P L Q100 L Q400 L Q800 L K L M
L Cmax
(g/mL)
— 3.10 4.04* 5.58* 7.78* 16.0* —
L AUC
(g*h/mL)
— 40.8 50.1* 67.3* 88.1* 208* —
AUEC
(mm*h)
3.2 6.7 11.8 14.4 7.31 10.6 25.2
Emax (mm) 0.81 0.81 0.61 1.17 0.79 0.97 2.49
* p  0.01 vs P  L;  p  0.05 vs. P.
PD effects for all Q doses and K  L treatments were less than for M
(p  0.01).
CONCLUSIONS: The combination of L and K or Q produced
modest central effects. While Q was somewhat more potent than K at
inhibiting blood-brain barrier (BBB) Pgp, the PD effect for both
combinations was much less than M. These results suggest the
clinical relevance of the interaction between L and either Q or K at
the BBB is marginal.
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PROJECTION OF DOSES FOR QT-PROLONGATION STUD-
IES BASED ON MODELING OF THE WORST-CASE INHIBI-
TION OF CYP3A. J. Y. Chien, PhD, S. D. Hall, PhD, S. A.
Wrighton, PhD, Eli Lilly & Company, Indiana University, India-
napolis, IN.
AIMS: To project the probability of “worst-case scenario” for
CYP3A-mediated ketoconazole (K) inhibition of CYP3A drugs
based on modeling of pharmacokinetic inhibition effect to select
doses for high-dose QT prolongation studies for a low extraction ratio
(ER) Drug A (range: 0.01–0.03) and high ER Drug B (range: 0.5–1).
Both of these drugs are orally absorbed and cleared by CYP3A by
unknown fractions (fm).
METHODS: The predicted K portal vein and systemic concen-
tration were used to drive its inhibitory effect on intrinsic clearance
and bioavailability of Drugs A and B. Simulations were performed to
test worst-case scenarios, including the duration of K dosing and the
range of drug’s fm and ER.
RESULTS: Performance of the model was assessed by comparing
simulated trials to actual clinical trial results for A and B given with
200 mg K. The model well predicted the 2-fold (A) and 6-fold (B)
AUC increases observed in the trials. Assuming worst-case fm and
bioavailability, 400 mg K produced less than doubling of AUC
compared to results at 200 mg K for both drugs; maximum inhibition
was obtained following 3 daily K doses. Doses for QT studies were
then selected to achieve the 90th or the 50th quantile of the distribution
of AUC ratios, or a 4- and 8-fold exposure-multiple from the target
clinical doses, for Drugs A and B, respectively.
CONCLUSIONS: Model-based projection of the probable worst-
case CYP3A inhibition can be used for high-dose QT prolongation
study design.
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